CLINICAL TRIALS PROFILE FOR TRILAFON

All Clinical Trials for TRILAFON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000654 ↗	The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU	Completed	Oclassen Pharmaceuticals	Phase 2	1969-12-31	To determine the tolerance of HIV-infected patients to TID oral doses of FIAU syrup at 4 different dose levels. To determine the peak and trough blood levels of FIAU and its metabolites during two weeks of oral dosing with FIAU. The pyrimidine nucleoside analog FIAC and its primary deaminated uracil metabolite FIAU are highly and specifically active compounds in vitro against several herpes group viruses, particularly herpes simplex virus (HSV) types 1 and 2, varicella zoster (VZV), and cytomegalovirus (CMV), as well as hepatitis B virus (HBV). Since FIAU is the primary metabolite of FIAC and the administration of FIAU simplifies the metabolism of FIAC, it is anticipated from clinical studies of FIAC that FIAU will be tolerated at least as well as FIAC. A single-dose, pharmacokinetic (blood level) study showed that FIAC, when taken orally, is readily absorbed into the bloodstream, and most of it is converted to FIAU. Daily oral doses are expected to provide concentrations of FIAU exceeding the in vitro minimum inhibitory concentration for nearly all the herpes group viruses.
NCT00000654 ↗	The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To determine the tolerance of HIV-infected patients to TID oral doses of FIAU syrup at 4 different dose levels. To determine the peak and trough blood levels of FIAU and its metabolites during two weeks of oral dosing with FIAU. The pyrimidine nucleoside analog FIAC and its primary deaminated uracil metabolite FIAU are highly and specifically active compounds in vitro against several herpes group viruses, particularly herpes simplex virus (HSV) types 1 and 2, varicella zoster (VZV), and cytomegalovirus (CMV), as well as hepatitis B virus (HBV). Since FIAU is the primary metabolite of FIAC and the administration of FIAU simplifies the metabolism of FIAC, it is anticipated from clinical studies of FIAC that FIAU will be tolerated at least as well as FIAC. A single-dose, pharmacokinetic (blood level) study showed that FIAC, when taken orally, is readily absorbed into the bloodstream, and most of it is converted to FIAU. Daily oral doses are expected to provide concentrations of FIAU exceeding the in vitro minimum inhibitory concentration for nearly all the herpes group viruses.
NCT00480246 ↗	A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer	Completed	BioLineRx, Ltd.	Phase 1	2007-05-01	This is a single dose, open-label, 2-panel (Parts A and B) PET study investigating the degree of occupancy of dopamine 2 receptors (D2_RO) in the human brain after single oral doses of BL-1020 or Perphenazine (Trilafon®, hereafter called Perphenazine) in healthy male subjects. In Part A the D2_RO is investigated for the study compound BL-1020 and in Part B the D2_RO of BL-1020 is compared to the D2_RO of Perphenazine, a reference compound.
NCT00802100 ↗	Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia	Completed	National Institute of Mental Health (NIMH)	Phase 4	2008-12-01	This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.

Clinical Trial Conditions for TRILAFON

Condition Name

Condition Name for TRILAFON
Intervention	Trials
Schizophrenia	2
Healthy	1
Hepatitis B	1
Herpes Simplex	1

Condition MeSH

Condition MeSH for TRILAFON
Intervention	Trials
Schizophrenia	2
Herpes Simplex	1
Psychotic Disorders	1
Hepatitis B	1

Clinical Trial Locations for TRILAFON

Trials by Country

Trials by Country for TRILAFON
Location	Trials
United States	16
Sweden	1

Trials by US State

Trials by US State for TRILAFON
Location	Trials
Texas	2
Maryland	2
California	2
North Carolina	1
New York	1

Clinical Trial Progress for TRILAFON

Clinical Trial Phase

Clinical Trial Phase for TRILAFON
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for TRILAFON
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for TRILAFON

Sponsor Name

Sponsor Name for TRILAFON
Sponsor	Trials
University of Texas Southwestern Medical Center	1
Oclassen Pharmaceuticals	1
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsor Type

Sponsor Type for TRILAFON
Sponsor	Trials
Industry	3
NIH	2
Other	1

TRILAFON Market Analysis and Financial Projection

Last updated: February 4, 2026

What Is the Current Status of Clinical Trials for TRILAFON?

TRILAFON (perphenazine) is an antipsychotic medication primarily used to treat schizophrenia and severe nausea. The drug, originally approved by the FDA in the 1950s, is marketed by several generic manufacturers. No recent reports indicate ongoing or upcoming clinical trials focused on TRILAFON itself, suggesting that current research activity is limited or non-existent.

Historically, clinical trials for TRILAF have centered on its efficacy compared to newer antipsychotics, with a focus on long-term safety and side effect profiles. No significant Phase I-III trials are active or listed in ClinicalTrials.gov as of the latest data in 2023.

This stagnation indicates the drug’s primary role is now established, with little move toward reformulation or new indications requiring clinical validation.

What Is the Market Analysis for TRILAFON?

Market Size and Revenue

TRILAFON's market is primarily driven by its generic status, with limited premium pricing. The global antipsychotics market was valued at approximately USD 11 billion in 2022 and is projected to reach USD 17 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 6%.

TRILAFON’s contribution to this market remains modest due to multiple factors:

• Competition from newer antipsychotics (risperidone, olanzapine, aripiprazole)
• The move toward second-generation antipsychotics, which have improved side effect profiles
• Prescriber preference shifts towards medications with fewer extrapyramidal symptoms

In the U.S., TRILAFON’s sales are concentrated among longstanding users and institutions, accounting for less than 3% of the total antipsychotic market. The drug's annual revenue is roughly USD 50-100 million globally, predominantly from generics in North America and Europe.

Competitive Landscape

The therapeutic landscape favors second-generation antipsychotics, with high efficacy and tolerability. These drugs dominate prescriptions, pushing older drugs like TRILAFON into niche or specialized use cases such as refractory cases or specific symptom profiles.

The key competitors include:

• Risperidone (risperdal)
• Olanzapine (zyprexa)
• Aripiprazole (abilify)
• Quetiapine (seroquel)

TRILAFON’s specific advantages are limited due to its side effect profile, including higher risks of extrapyramidal symptoms and tardive dyskinesia, discouraging broad use.

What Are the Market Projections for TRILAFON?

Given the lack of clinical development and the dominance of second-generation agents, TRILAFON’s long-term market share is expected to decline further. The growth prospects are minimal; the drug is unlikely to see significant approval for new indications without substantial clinical trials.

Market analysts project an annual decline rate of about 2-3% in the total sales volume for first-generation antipsychotics over the next five years, driven by Prescriber preference for newer agents.

Potential market expansion could occur if TRILAFON is repositioned for off-label uses or as a treatment for specific conditions such as Nausea and Vomiting, but this would require dedicated clinical research and regulatory approval extensions.

Are There Any Regulatory or Policy Developments Affecting TRILAFON?

Regulatory agencies continually review antipsychotics for safety and efficacy. Recently, the FDA raised concerns about metabolic side effects in second-generation antipsychotics, which may temporarily boost interest in older medications like TRILAFON—if safety issues are better understood or mitigated.

Yet, no regulatory mandates or incentives currently favor the re-evaluation or labeling update for TRILAFON. The drug remains approved for its established indications, with no new approvals or label changes recent in the public domain.

What Are the Implications for Stakeholders?

Pharmaceutical companies with licensing rights face limited opportunities for growth unless they innovate or reposition TRILAFON. Clinical trial investment would be necessary to establish new uses or improve safety profiles.

Healthcare providers tend to favor newer agents; hence, market penetration for repositioned or reformulated TRILAFON will be challenging without significant clinical evidence.

Investors should note the drug's aging profile, with declining sales likely unless a new indication or formulation can be supported by evidence.

Key Takeaways

• No active clinical trials for TRILAFON as of 2023; primarily an aging, generic drug.
• Market size remains small, less than USD 100 million annually, with declining sales.
• Competition from second-generation antipsychotics limits TRILAFON’s growth.
• Future market prospects hinge on repositioning via clinical research and regulatory approval.
• The drug’s relevance is expected to diminish further in the next five years without significant innovation.

FAQs

1. Are there plans to conduct new clinical trials for TRILAFON? No publicly available data indicates upcoming clinical trials focused on TRILAFON.

2. Could TRILAFON be repurposed for other indications? Repositioning would require new clinical studies, which have not been announced or initiated.

3. How does TRILAFON compare cost-wise to newer antipsychotics? Generic TRILAFON remains a low-cost option, but its clinical disadvantages limit its market share despite affordability.

4. What safety concerns are associated with TRILAFON? Extrapyramidal symptoms and tardive dyskinesia are more common compared to second-generation antipsychotics.

5. What is the outlook for TRILAFON’s market share? Expect continued decline unless clinical development introduces new uses or formulations.

---

Sources:

1. Market data from Grand View Research, 2023.
2. ClinicalTrials.gov database, accessed 2023.
3. FDA drug database, 2023.
4. IHS Markit, "Global Antipsychotic Market Review," 2022.
5. Prescribing trends from IQVIA, 2023.